Higano CS, et al. Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients. ASCO-GU 2019, abstract 256.
Three-year Safety of Radium-223 in Patients with mCRPC and Symptomatic Bone Metastases
jul 2017 | Uro-oncologie